Rune Labs, which specializes in precision medicine for Parkinson’s disease (PD), has launched of a clinical program with ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.0, a high estimate of $185.00, and a low estimate of $115.00. Highlighting a 1 ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, ...